Spectrum of offending drugs and cutaneous adverse drug reactions requiring hospitalisation in a tertiary South African hospital in TB/HIV endemic setting

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The IMARI-Africa project is part of the EDCTP2 programme supported by the European Union (Grant number TMA2017SF- 1981). Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI152183. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Philips E, reports grants from National Institutes of Health (R01HG010863, R01AI152183, 01AI154659), grant support from UAI109565 and from the National Health and Medical Research Council of Australia. She receives Royalties from UpToDate and fees from Janssen, Vertex, Biocryst and Regeneron. She is co-director of IIID Pty that holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity and has a patent pending for Detection of Human Leukocyte Antigen-A*32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. Lehloenya R, is supported by the South African Medical Research Council and non-rated researcher support from the South African National Research Foundation. Peter J was supported by an NIH Fogarty career development award (K43TW011178-04) during this work. Mankahla A is supported by the South African Medical Research Council, by a self-initiated research grant.